Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
GIP/GLP-1/FGF21 Fusion Protein treating NASH, T2DM, Hyperlipoidemia | NASH, T2DM, Hyperlipoidemia | Preclinical |
Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
FG1-H82Q3 | Human | Biotinylated Human FGF-21 Protein, His,Avitag™ |
|
||
FG1-H5243 | Human | Human FGF-21 Protein, His Tag |
|
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Pegozafermin | BIO89-100; TEV-47948 | Phase 3 Clinical | Teva Pharmaceutical Industries Ltd | Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
Efruxifermin | AKR-001; AMG-876; EFX; Fc-FGF21(RGE) | Phase 3 Clinical | Amgen Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus | Details |
Recombinant human FGF21 Fc fusion protein(Anyuan Pharmaceutical) | AP-025 | Phase 2 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd | Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
HEC-88473 | HEC-88473; HEC88473 | Phase 2 Clinical | Dongguan Hec Taigen Biopharmaceuticals Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Hepatitis; Obesity | Details |
YH-25724 | YH-25724; YH25724 | Phase 1 Clinical | Yuhan Corp | Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
AP-026 | AP-026; TQA-2226; TQA2226; AP026 | Phase 1 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Hyperlipidemias; Overweight | Details |
Pegozafermin | BIO89-100; TEV-47948 | Phase 3 Clinical | Teva Pharmaceutical Industries Ltd | Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
Efruxifermin | AKR-001; AMG-876; EFX; Fc-FGF21(RGE) | Phase 3 Clinical | Amgen Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus | Details |
Recombinant human FGF21 Fc fusion protein(Anyuan Pharmaceutical) | AP-025 | Phase 2 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd | Hypertriglyceridemia; Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
HEC-88473 | HEC-88473; HEC88473 | Phase 2 Clinical | Dongguan Hec Taigen Biopharmaceuticals Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Hepatitis; Obesity | Details |
YH-25724 | YH-25724; YH25724 | Phase 1 Clinical | Yuhan Corp | Metabolic Dysfunction-Associated Steatotic Liver Disease | Details |
AP-026 | AP-026; TQA-2226; TQA2226; AP026 | Phase 1 Clinical | Anyuan Pharmaceutical Technology (Shanghai) Co Ltd | Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Obesity; Hyperlipidemias; Overweight | Details |
This web search service is supported by Google Inc.